LAG3 antibody (Biotin)

Catalog No. ABIN2660995

This anti-LAG3 antibody is a Rat Monoclonal antibody detecting LAG3 in IHC, FACS and IF. Suitable for Mouse.

Quick Overview for LAG3 antibody (Biotin) (ABIN2660995)

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This LAG3 antibody is conjugated to Biotin

Application: Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: C9B7W

Product Details anti-LAG3 Antibody (Biotin)

Purification: The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for LAG3

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Alternative Name: CD223

Background: CD223, also known as LAG-3, is 70 kD type I transmembrane glycoprotein within the Ig superfamily. It is the gene product of lymphocyte activation gene-3 (Lag3) with structural similarity to CD4. CD223 is expressed on activated T cells and NK cells, as well as T regulatory cells. CD223, like CD4, binds MHC class II molecules, but with higher affinity than CD4. In association with the CD3 complex, CD223 has been shown as a negative regulatory molecule to inhibit TCR-mediated signaling and regulate homeostatic T cell expansion. In contrast to inhibition, CD223 has an activation function to promote immune responses by inducing MHC class II signaling in antigen presenting cells.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints